LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

AstraZeneca's Imfinzi, when combined with standard-of-care BCG induction and maintenance therapy, showed DFS improvement.

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

Cognition Therapeutics has announced positive topline outcomes from the Phase II MAGNIFY trial of zervimesine in adult ...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement genAI across the agency by 30 June ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

Boehringer Ingelheim has begun the JADE Phase II trial to evaluate BI 1584862 as a first-in-class oral treatment for ...

It is vital for biotech companies to run the right clinical trial and not cut costs, the Sanofi executive said.